Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Karen Claesen"'
Autor:
Karen Claesen, Joni De Loose, Pieter Van Wielendaele, Emilie De bruyn, Yani Sim, Sofie Thys, Ingrid De Meester, Dirk Hendriks
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 4, p 3725 (2023)
Carboxypeptidase U (CPU, TAFIa, CPB2) is a potent attenuator of fibrinolysis that is mainly synthesized by the liver as its inactive precursor proCPU. Aside from its antifibrinolytic properties, evidence exists that CPU can modulate inflammation, the
Externí odkaz:
https://doaj.org/article/7eb0898b705e4a828dee21cc636b688c
Publikováno v:
Pharmaceutics, Vol 13, Iss 10, p 1731 (2021)
Statins (hydroxymethyl-glutaryl-CoA-reductase inhibitors) lower procarboxypeptidase U (proCPU, TAFI, proCPB2). However, it is challenging to prove whether this is a lipid or non-lipid-related pleiotropic effect, since statin treatment decreases chole
Externí odkaz:
https://doaj.org/article/04f1f8ee3622409b9d5d554eb53e2936
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 2, p 883 (2021)
Procarboxypeptidase U (proCPU, TAFI, proCPB2) is a basic carboxypeptidase zymogen that is converted by thrombin(-thrombomodulin) or plasmin into the active carboxypeptidase U (CPU, TAFIa, CPB2), a potent attenuator of fibrinolysis. As CPU forms a mol
Externí odkaz:
https://doaj.org/article/6a105895572745e9905af7fd807a9727
Autor:
Karen Claesen, Yani Sim, Shahir Basir, Simon De Belder, Tinne van den Keybus, Glenn Van Edom, Hilde Stoffelen, Gilles W De Keulenaer, Johan Bosmans, Tijs Bringmans, Ingrid De Meester, Dirk Hendriks
Publikováno v:
Journal of Thrombosis and Haemostasis. 21:1266-1273
Autor:
Johan Bosmans, Ingrid De Meester, Karen Claesen, Jeroen Maes, Joachim C. Mertens, Shahir Basir, Simon De Belder, Dirk Hendriks, Hilde Stoffelen
Publikováno v:
Clinical therapeutics
Purpose Statins are commonly used in patients with hypercholesterolemia to lower their cholesterol levels and to reduce their cardiovascular risk. There is also considerable evidence that statins possess a range of cholesterol-independent effects, in
Autor:
Karen Claesen, Yani Sim, An Bracke, Michelle De bruyn, Emilie De Hert, Gwendolyn Vliegen, An Hotterbeekx, Alexandra Vujkovic, Lida van Petersen, Fien H. R. De Winter, Isabel Brosius, Caroline Theunissen, Sabrina van Ierssel, Maartje van Frankenhuijsen, Erika Vlieghe, Koen Vercauteren, Samir Kumar-Singh, Ingrid De Meester, Dirk Hendriks
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 6; Pages: 1494
Journal of Clinical Medicine
Journal of Clinical Medicine
Coronavirus disease 2019 (COVID-19) is a viral lower respiratory tract infection caused by the highly transmissible and pathogenic SARS-CoV-2 (severe acute respiratory-syndrome coronavirus-2). Besides respiratory failure, systemic thromboembolic comp
Autor:
An Bracke, Emilie De Hert, Michelle De bruyn, Karen Claesen, Gwendolyn Vliegen, Alexandra Vujkovic, Lida van Petersen, Fien H.R. De Winter, An Hotterbeekx, Isabel Brosius, Caroline Theunissen, Sabrina Van Ierssel, Maartje van Frankenhuijsen, Erika Vlieghe, Koen Vercauteren, Pieter Van der Veken, Dirk Hendriks, Samir Kumar-Singh, Ingrid De Meester
Publikováno v:
Clinica chimica acta
Background: COVID-19 patients experience several features of dysregulated immune system observed in sepsis. We previously showed a dysregulation of several proline-selective peptidases such as dipeptidyl peptidase 4 (DPP4), fibroblast activation prot
Autor:
Pere Cardona, Karen Claesen, Benoit Tyl, Dirk Hendriks, Carlos A. Molina, Vanessa Blanc-Guillemaud, Joachim C. Mertens
Publikováno v:
Translational stroke research
Translational Stroke Research
Translational Stroke Research
The antifibrinolytic enzyme carboxypeptidase U (CPU, TAFIa, CPB2) is an appealing target for the treatment of acute ischemic stroke (AIS). Increased insights in CPU activation and inactivation during thrombolysis (rtPA) with or without endovascular t
Autor:
R. Campbell Tait, Sarah K Westbury, Dirk Hendriks, Kate Downes, Claire S. Whyte, Andrew D Mumford, Nicola J. Mutch, Jonathan Stephens, Karen Claesen, Nihr BioResource, Ernest Turro, Joachim C. Mertens, Emma J Leishman, Anne-Louise Latif
Publikováno v:
Westbury, S K, Whyte, C S, Stephens, J, Downes, K, Turro, E, Claesen, K, Mertens, J, Hendriks, D, Latif, A-L, Leishman, E, Mutch, N J & Tait, C R & Mumford, A D 2020, ' A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency ', Journal of Thrombosis and Haemostasis . https://doi.org/10.1111/jth.14990
Journal of thrombosis and haemostasis
Journal of thrombosis and haemostasis
Background: Thrombomodulin-associated coagulopathy (TM-AC) is a rare bleeding disorder in which a single reported p.Cys537* variant in the thrombomodulin gene THBD causes high plasma thrombomodulin (TM) levels. High TM levels attenuate thrombin gener
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c157a370d0e881f53aa770a2ad3679b4
https://research-information.bris.ac.uk/en/publications/6789ca66-5e8d-46c1-99cc-29e55d539469
https://research-information.bris.ac.uk/en/publications/6789ca66-5e8d-46c1-99cc-29e55d539469
Publikováno v:
Pharmaceutics, Vol 13, Iss 1731, p 1731 (2021)
Pharmaceutics
Pharmaceutics
Statins (hydroxymethyl-glutaryl-CoA-reductase inhibitors) lower procarboxypeptidase U (proCPU, TAFI, proCPB2). However, it is challenging to prove whether this is a lipid or non-lipid-related pleiotropic effect, since statin treatment decreases chole